Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

mpany's significant geographical markets, as well as any political and/or economic uncertainty and disruptions due to terrorist activities; (9) the ability to successfully manage competitive factors, including prices, promotional incentives and trade terms for products; (10) the ability to obtain patents and respond to technological advances attained by competitors and patents granted to competitors; (11) the ability to successfully manage increases in the prices of raw materials used to make the Company's products; (12) the ability to stay close to consumers in an era of increased media fragmentation; and (13) the ability to stay on the leading edge of innovation and maintain a positive reputation on our brands. For additional information concerning factors that could cause actual results to materially differ from those projected herein, please refer to our most recent 10-K, 10-Q and 8-K reports.


'/>"/>
SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , Oct. 17, 2014   DaVita ... ), one of the nation,s largest and most ... DaVita University Academy – the company,s award-winning, leadership ... Nearly 2,000 DaVita teammates from around the globe ... DaVita University Academy is a two-day one-of-a-kind ...
(Date:10/16/2014)... MARLBOROUGH, Mass. , Oct. 16, 2014 ... received CE Mark approval for the ACCOLADE TM ... leads, ACCOLADE pacemakers are the first to enable ... Tesla and 3.0 Tesla systems. In addition, the Boston ... MRI options, allowing higher energy scan sequences, and featuring ...
(Date:10/16/2014)... 2014 The Parenteral Drug Association ... application of single-use, or disposable, systems in ... products with the publication of Technical ... Single-Use Systems in Pharmaceutical Manufacturing. ... systems (SUS) or single-use equipment, has the ...
Breaking Medicine Technology:DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 2DaVita HealthCare Partners Celebrates New-Teammate Training and Leadership Milestone 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 2Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 3Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 4Boston Scientific Announces Pacemaker CE Mark With Options For Magnetic Resonance Imaging 5PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations 2
... 18, 2011 The U.S. Food and Drug Administration ... treat patients with acute lymphoblastic leukemia (ALL), who have ... derived asparaginase and pegaspargase chemotherapy drugs used to treat ... Acute lymphoblastic leukemia is a type of ...
... and OXFORD, England, Nov. 18, 2011   EUSA Pharma, a ... supportive care and critical care, today announced that ... approved its orphan drug ERWINAZE™ (asparaginase Erwinia ... leukemia (ALL) in patients with hypersensitivity to ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 2EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 3EUSA Pharma Announces FDA Approval of Orphan Drug ERWINAZE™ for Treatment of Acute Lymphoblastic Leukemia 4
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... 2014 Principle Business Enterprises, a family ... manufacturing top-of-the-line absorbent products. The company has recently ... popular brand, Tranquility® Premium Protection absorbent products. The ... gave its packaging a new look, and is currently ... to the public. , The new website, developed with ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 AttorneyOne.com, a ... the latest information from the FDA on Sit and ... October 10 not to purchase or use Sit and Slim ... and Slim II is promoted as weight loss product on ... removed from the market in 2010 for safety reasons, can ...
(Date:10/20/2014)... 2014 Myoderm announced ... Director of their CentralSource service. Matthew ... innovative turnkey drug sourcing, distribution, and management service ... 12 years of industry experience, in both business ... peak of their international success to help clients ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... in US are not getting ample amounts of a nutrient ... development.// ,A new study sponsored by the National ... the top universities in America has suggested that the women ... is required to promote normal fetal brain development. ...
... deleterious effect on young, developing brains, according to researchers ... linked to lower IQ scores later in life. // ... diabetes, high cholesterol and hypertension is a well documented ... genetics at the University of Florida said, 'We're postulating ...
... after they received blood transfusion thought to be contaminated ... been// infected in the last few months in various ... died were all younger than two years old," a ... suspected donors who are thought to have HIV.HIV/AIDS infection ...
... the University of Virginia Health System have found that ... drive better when they took// OROS methylphenidate (OROS MPH), ... (se-AMPH ER). The findings, which reinforce the use of ... ADHD, will appear in the Sept. issue of Pediatrics. ...
... has been released by Australian obesity experts that show gastric ... conference on obesity in Sydney there were three studies which ... in mortality rates in obese people who had the surgery. ... upper part of the stomach for the procedure to restrict ...
... in children that can often be disabling and one ... from school could mainly be due to their genetic// ... Medicine (Department of Psychological Medicine), in a genetic study ... usually occur together, they are of different genetic and ...
Cached Medicine News:Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 2Health News:Americans Deficient In Dietary Intake Of Choline Needed for Fetal Brain Development 3Health News:Obesity Takes its Toll on IQ of Toddlers 2Health News:Not All ADHD Drugs Are Equal 2
Listeria Enrichment Broth...
... Thermomixer R offers maximum application versatility ... heating, and cooling. Its active heating/cooling ... and temperature control ranges. Five different ... micro test tubes, are available for: ...
... units Penicillin/25,000 ug Streptomycin ... Reagent and Buffer products ... with cGMP regulations and ... to assure compatibility. , ...
...
Medicine Products: